| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Thomas I F H Cremers, Kieran Rea, Fokko J Bosker, Håkan V Wikström, Sandra Hogg, Arne Mørk, Ben H C Westerin. Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 7. 2007-08-31. PMID:17203017. |
to investigate which neurotransmitter systems were involved in the interaction, systemic citalopram was challenged with several glutamatergic, gaba-ergic, noradrenergic, and dopaminergic compounds to determine their effects on serotonin release in ventral hippocampus. |
2007-08-31 |
2023-08-12 |
Not clear |
| I Martínez-Gras, J Hoecnika, E Pérez-Hernández, R Rodríguez-Jiménez, G Ponce, Ma Jiménez-Arriero, J Ramos-Atance, T Palomo, G Rubi. [Endocannabinoid system and CNR1 gene polymorphisms in schizophrenia and addictive disorders]. Actas espanolas de psiquiatria. vol 35. issue 2. 2007-08-10. PMID:17401783. |
on the other hand this system may be involved in several brain functions through neuromodulation dopaminergic and other neurotransmitter system involved in schizophrenic and substance abuse disorders. |
2007-08-10 |
2023-08-12 |
Not clear |
| Janice H Silva, Renato S Gomez, Paulo H C Diniz, Marcus V Gomez, Cristina Guatimosi. The effect of sevoflurane on the release of [3H]dopamine from rat brain cortical slices. Brain research bulletin. vol 72. issue 4-6. 2007-07-24. PMID:17452291. |
dopamine is a neurotransmitter that exerts major control on important brain functions and some lines of studies suggest that dopaminergic neurotransmission may be a potential target for volatile anesthetics. |
2007-07-24 |
2023-08-12 |
rat |
| Dan Rujescu, Andreas Thalmeier, Hans-Jürgen Möller, Thomas Bronisch, Ina Gieglin. Molecular genetic findings in suicidal behavior: what is beyond the serotonergic system? Archives of suicide research : official journal of the International Academy for Suicide Research. vol 11. issue 1. 2007-05-02. PMID:17178640. |
furthermore, genes of the dopaminergic and noradrenergic neurotransmitter systems have also been the subjects of investigations in this context. |
2007-05-02 |
2023-08-12 |
human |
| Mona Boules, Amanda Shaw, Paul Fredrickson, Elliott Richelso. Neurotensin agonists: potential in the treatment of schizophrenia. CNS drugs. vol 21. issue 1. 2007-05-01. PMID:17190526. |
it is closely associated with, and is thought to modulate, dopaminergic and other neurotransmitter systems involved in the pathophysiology of various neuropsychiatric diseases, including schizophrenia. |
2007-05-01 |
2023-08-12 |
Not clear |
| Anne-Kathrin Ettl, Jochen Holzschuh, Wolfgang Drieve. The zebrafish mutation m865 affects formation of dopaminergic neurons and neuronal survival, and maps to a genetic interval containing the sepiapterin reductase locus. Anatomy and embryology. vol 211 Suppl 1. 2007-04-05. PMID:17024299. |
the effects of the mutation appear not to be restricted to dopaminergic neurons, as development of other neurotransmitter systems (serotonergic and cholinergic) is impaired as well. |
2007-04-05 |
2023-08-12 |
zebrafish |
| Daniel Kondziella, Eiliv Brenner, Elvar M Eyjolfsson, Ursula Sonnewal. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Neurochemistry international. vol 50. issue 2. 2007-03-30. PMID:17084946. |
instead, a more integrative approach combines different neurotransmitter systems, in which glutamatergic, gabaergic and dopaminergic pathways interact. |
2007-03-30 |
2023-08-12 |
human |
| Xiaohui Xu, Keeley Brookes, Chih-Ken Chen, Yu-Shu Huang, Yu-Yu Wu, Philip Asherso. Association study between the monoamine oxidase A gene and attention deficit hyperactivity disorder in Taiwanese samples. BMC psychiatry. vol 7. 2007-03-19. PMID:17328795. |
molecular genetic and pharmacological studies suggest the involvement of the dopaminergic, serotonergic and noradrenergic neurotransmitter systems in the pathogenesis of adhd. |
2007-03-19 |
2023-08-12 |
Not clear |
| Ujendra Kumar, Shutish C Pate. Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain. Brain research. vol 1131. issue 1. 2007-03-09. PMID:17182012. |
another key neurotransmitter system involved with emotion and cognition is the dopaminergic system. |
2007-03-09 |
2023-08-12 |
rabbit |
| Marije van Beilen, Klaus L Leender. Putamen FDOPA uptake and its relationship tot cognitive functioning in PD. Journal of the neurological sciences. vol 248. issue 1-2. 2007-01-23. PMID:16782131. |
in pd, multiple neurotransmitter systems are involved in cognitive functioning, including the dopaminergic system. |
2007-01-23 |
2023-08-12 |
Not clear |
| Richard S Jope, Myoung-Sun Ro. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Current drug targets. vol 7. issue 11. 2007-01-04. PMID:17100582. |
several intracellular signaling cascades converge on gsk3 to modulate its activity, and several neurotransmitter systems also regulate gsk3, including serotonergic, dopaminergic, cholinergic, and glutamatergic systems. |
2007-01-04 |
2023-08-12 |
Not clear |
| Ales Stuchlik, Karel Vale. Effect of dopamine D1 receptor antagonist SCH23390 and D1 agonist A77636 on active allothetic place avoidance, a spatial cognition task. Behavioural brain research. vol 172. issue 2. 2006-12-28. PMID:16781786. |
these findings support the notion that brain dopaminergic d1 neurotransmitter system modulates neural processes underlying spatial cognition. |
2006-12-28 |
2023-08-12 |
rat |
| Leonid Yavich, Pekka Jäkälä, Heikki Tanil. Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice. Journal of neurochemistry. vol 99. issue 3. 2006-12-20. PMID:16824047. |
the effects are essentially the same as previously reported for dopaminergic terminals in the striatum, indicating that the important role of alpha-synuclein in neurotransmitter mobilization is not limited to dopaminergic terminals. |
2006-12-20 |
2023-08-12 |
mouse |
| Robert B Raffa, Gregory W Stagliano, Ronald J Tallarid. Subadditive withdrawal from cocaine/kappa-opioid agonist combinations in Planaria. Brain research. vol 1114. issue 1. 2006-11-28. PMID:16914122. |
planaria are particularly valuable for these studies because of their permeable exteriors and their relevant neurotransmitter systems (e.g., dopaminergic, opioid, and serotonergic). |
2006-11-28 |
2023-08-12 |
Not clear |
| Mona Boules, Paul Fredrickson, Elliott Richelso. Bioactive analogs of neurotensin: focus on CNS effects. Peptides. vol 27. issue 10. 2006-11-20. PMID:16882457. |
it is closely associated anatomically with dopaminergic and other neurotransmitter systems, and evidence supports a role for nt agonists in the treatment of various neuropsychiatric disorders. |
2006-11-20 |
2023-08-12 |
Not clear |
| Mona Boules, Paul Fredrickson, Elliott Richelso. Neurotensin agonists as an alternative to antipsychotics. Expert opinion on investigational drugs. vol 14. issue 4. 2006-11-14. PMID:15882113. |
in brain, this peptide is prominently associated anatomically with dopaminergic, as well as other neurotransmitter systems. |
2006-11-14 |
2023-08-12 |
Not clear |
| Spiros Konitsioti. Novel pharmacological strategies for motor complications in Parkinson's disease. Expert opinion on investigational drugs. vol 14. issue 4. 2006-11-14. PMID:15882115. |
the nonphysiological, pulsatile stimulation produced by most currently available dopaminergic therapies triggers a complicated series of responses resulting in the dysregulation of glutamate receptors and many other neurotransmitter systems on striatal neurons. |
2006-11-14 |
2023-08-12 |
Not clear |
| Ubaldo Bonuccelli, Paolo Del Dott. New pharmacologic horizons in the treatment of Parkinson disease. Neurology. vol 67. issue 7 Suppl 2. 2006-10-30. PMID:17030738. |
the nonphysiologic pulsatile stimulation of striatal dopamine receptors, produced by the currently available dopaminergic drugs, may trigger a dysregulation of many neurotransmitter systems within the basal ganglia, mainly localized on medium spiny striatal neurons. |
2006-10-30 |
2023-08-12 |
Not clear |
| Bin Li. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. The AAPS journal. vol 8. issue 3. 2006-10-24. PMID:17025278. |
parkinson's disease (pd) is a debilitating movement disorder resulting from a progressive degeneration of the nigrostriatal dopaminergic pathway and depletion of neurotransmitter dopamine in the striatum. |
2006-10-24 |
2023-08-12 |
Not clear |
| W Michael Caudle, Jason R Richardson, Kristin C Delea, Thomas S Guillot, Minzheng Wang, Kurt D Pennell, Gary W Mille. Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity. Toxicological sciences : an official journal of the Society of Toxicology. vol 92. issue 2. 2006-09-29. PMID:16702228. |
the observed reductions appear to be specific to the dat populations located in the striatum, as no change was observed in other dopaminergic brain regions or to other neurotransmitter transporters present in the striatum. |
2006-09-29 |
2023-08-12 |
human |